Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 39Carcinoma, Hepatocellular 38Small Cell Lung Carcinoma 26Breast Neoplasms 19Neoplasms 18Cholangiocarcinoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 15Triple Negative Breast Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Pancreatic Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Recurrence 9Ovarian Neoplasms 9Neoplasm Metastasis 9Esophageal Neoplasms 8Carcinoma, Renal Cell 8Stomach Neoplasms 7Head and Neck Neoplasms 7Carcinoma, Transitional Cell 7Prostatic Neoplasms 6Melanoma 6Endometrial Neoplasms 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Neoplasms by Site 5Mesothelioma, Malignant 5Adenocarcinoma 5

Interventions

Cyclophosphamide 46fludarabine phosphate 24Busulfan 22Peripheral Blood Stem Cell Transplantation 20Radiotherapy 19Filgrastim 19Mycophenolic Acid 18Antilymphocyte Serum 18Cyclosporine 17Whole-Body Irradiation 16Rituximab 16Etoposide 16Methotrexate 15Melphalan 15Methylprednisolone 14Tacrolimus 12Cytarabine 12Vincristine 10Prednisone 10Doxorubicin 10Cord Blood Stem Cell Transplantation 10Thiotepa 6Granulocyte Colony-Stimulating Factor 6Leucovorin 5sargramostim 4fludarabine 4Daunorubicin 4glofitamab 3Sirolimus 3Methylprednisolone Hemisuccinate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Dendritic Cell Sarcoma, Interdigitating × durvalumab × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡